📊 CDLX Key Takeaways
Is Cardlytics, Inc. (CDLX) a Good Investment?
Cardlytics exhibits severe financial distress with negative stockholders' equity of -$4.0M, persistent operating losses (-$8.3M), and negative free cash flow (-$5.7M), indicating fundamental business model failure. High debt burden of $204.2M with zero interest coverage ability creates acute refinancing and solvency risk.
Cardlytics shows some fundamental improvement, with revenue growth near 10%, narrowing net losses, and modestly positive operating and free cash flow. However, the core business remains deeply unprofitable, leverage is heavy relative to its balance sheet, and negative equity signals a fragile financial position. Until sustained margin improvement and stronger balance sheet repair are evident, the fundamentals remain weak.
Cardlytics, Inc. Key Strengths (CDLX)
- Current ratio of 2.17x provides near-term liquidity cushion despite negative equity
- Revenue growing at 9.9% YoY indicates some residual market demand
- $35.7M cash balance offers limited runway for turnaround initiatives
- Revenue grew 9.9% year over year, indicating the business is still expanding
- Operating cash flow and free cash flow turned positive, supporting near-term liquidity
- Current and quick ratios of 1.75x suggest acceptable short-term liquidity despite losses
CDLX Stock Risks: Cardlytics, Inc. Investment Risks
- Negative stockholders' equity of -$4.0M represents technical insolvency with liabilities exceeding assets
- Negative operating cash flow of -$5.6M and FCF of -$5.7M show core business cannot fund operations
- Interest coverage of -8.8x demonstrates inability to service $204.2M debt from operations; refinancing risk is acute
- Operating margin of -24.1% and net margin of -13.1% with no clear profitability trajectory
- Negative ROA of -1.7% confirms asset base is not generating returns
- Operating and net margins remain severely negative, showing the business model has not reached sustainable profitability
- Negative stockholders equity and $212.57M of long-term debt create significant balance sheet risk
- Negative interest coverage indicates earnings are insufficient to support debt costs
Key Metrics to Watch
- Quarterly operating cash flow trend and achievement of positive cash generation
- Monthly cash burn rate relative to $35.7M runway; debt covenant compliance status
- Path to operating profitability and timeline to positive operating income
- Debt refinancing negotiations and potential equity dilution or restructuring
- Operating margin trend and whether losses continue narrowing toward breakeven
- Cash balance versus debt obligations, including sustained positive operating cash flow
Cardlytics, Inc. (CDLX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.17x current ratio provides a solid financial cushion.
CDLX Profit Margin, ROE & Profitability Analysis
CDLX vs Technology Sector: How Cardlytics, Inc. Compares
How Cardlytics, Inc. compares to Technology sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Cardlytics, Inc. Stock Overvalued? CDLX Valuation Analysis 2026
Based on fundamental analysis, Cardlytics, Inc. has mixed fundamental signals relative to the Technology sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Cardlytics, Inc. Balance Sheet: CDLX Debt, Cash & Liquidity
CDLX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Cardlytics, Inc.'s revenue has grown significantly by 10% over the 5-year period, indicating strong business expansion. The most recent EPS of $-3.69 indicates the company is currently unprofitable.
CDLX Revenue Growth, EPS Growth & YoY Performance
CDLX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $34.3M | -$4.5M | N/A |
| Q3 2025 | $47.0M | -$72.7M | $-1.36 |
| Q2 2025 | $58.0M | -$4.3M | $-0.09 |
| Q1 2025 | $56.4M | -$13.3M | $-0.26 |
| Q3 2024 | $61.1M | -$24.0M | $-0.63 |
| Q2 2024 | $64.0M | -$4.3M | $-0.09 |
| Q1 2024 | $59.0M | $13.6M | $0.40 |
| Q3 2023 | $67.3M | $6.3M | $0.19 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Cardlytics, Inc. Dividends, Buybacks & Capital Allocation
CDLX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Cardlytics, Inc. (CIK: 0001666071)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CDLX
What is the AI rating for CDLX?
Cardlytics, Inc. (CDLX) has a Combined AI Grade of C from Claude (D) and ChatGPT (C) with 87% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CDLX's key strengths?
Claude: Current ratio of 2.17x provides near-term liquidity cushion despite negative equity. Revenue growing at 9.9% YoY indicates some residual market demand. ChatGPT: Revenue grew 9.9% year over year, indicating the business is still expanding. Operating cash flow and free cash flow turned positive, supporting near-term liquidity.
What are the risks of investing in CDLX?
Claude: Negative stockholders' equity of -$4.0M represents technical insolvency with liabilities exceeding assets. Negative operating cash flow of -$5.6M and FCF of -$5.7M show core business cannot fund operations. ChatGPT: Operating and net margins remain severely negative, showing the business model has not reached sustainable profitability. Negative stockholders equity and $212.57M of long-term debt create significant balance sheet risk.
What is CDLX's revenue and growth?
Cardlytics, Inc. reported revenue of $34.3M.
Does CDLX pay dividends?
Cardlytics, Inc. does not currently pay dividends.
Where can I find CDLX SEC filings?
Official SEC filings for Cardlytics, Inc. (CIK: 0001666071) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CDLX's EPS?
Cardlytics, Inc. has a diluted EPS of $-1.95.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is CDLX's fundamental grade?
Based on our AI fundamental analysis in June 2026, Cardlytics, Inc. has a C grade with 87% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is CDLX stock overvalued or undervalued?
Valuation metrics for CDLX: ROE of N/A (sector avg: 22%), net margin of -13.1% (sector avg: 18%). Compare these metrics with sector averages to assess valuation.
What is CDLX's AI grade for 2026?
Our dual AI analysis gives Cardlytics, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CDLX's free cash flow?
Cardlytics, Inc.'s operating cash flow is $-5.6M, with capital expenditures of $28.0K. FCF margin is -16.5%.
How does CDLX compare to other Technology stocks?
Vs Technology sector averages: Net margin -13.1% (avg: 18%), ROE N/A (avg: 22%), current ratio 2.17 (avg: 2.5).